Mayne Pharma Group Provides Update on E4/DRSP

  • Oct 23, 2019 AEDT
  • Team Kalkine

Mayne Pharma Group Limited (ASX: MYX) has reported that Mithra Pharmaceuticals, SA presented the phase 3 trial results for E4/DRSP oral contraceptive at the 13th Annual Meeting of the European Society of Gynecology in Vienna, Austria.

  • Top-line results for the phase 3 studies had been reported earlier in Europe, Russia, Canada & United States.
  • MYX has signed a 20-year exclusive supply agreement with Mithra to commercialise E4/DRSP in the US.
  • E4/DRSP is likely to be commercialised in the first half of CY 2021, in adherence to the US FDA approval.

At 1:19 PM AEST, MYX was trading at $0.555, down by 3.4% relative to its previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK